WSO - March 2024 - 313

Nguyen et al.
313
11. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with
alteplase for acute ischaemic stroke in the safe implementation
of thrombolysis in stroke-monitoring study (SITS-MOST): an
observational study. Lancet 2007; 369: 275-282.
12. Wu S, Yuan R, Wang Y, et al. Early prediction of malignant
brain edema after ischemic stroke a systematic review and
meta-analysis. Stroke 2018; 49: 2918-2927.
13. Olivot JM, Mlynash M, Inoue M, et al. Hypoperfusion intensity
ratio predicts infarct progression and functional outcome
in the DEFUSE 2 Cohort. Stroke 2014; 45: 1018-1023.
14. Cepeda MS, Boston R, Farrar JT, et al. Comparison of logistic
regression versus propensity score when the number of events
is low and there are multiple confounders. Am J Epidemiol
2003; 158: 280-287.
15. Austin PC. Optimal caliper widths for propensity-score
matching when estimating differences in means and differences
in proportions in observational studies. Pharm Stat
2011; 10: 150-161.
16. Nguyen TN, Castonguay AC, Siegler JE, et al. Mechanical
thrombectomy in the late presentation of anterior circulation
large vessel occlusion stroke: a guideline from the society of
vascular and interventional neurology guidelines and practice
standards committee. Stroke 2023; 3: e000512.
17. Christensen S, Mlynash M, Kemp S, et al. Persistent target
mismatch profile >24 hours after stroke onset in DEFUSE 3.
Stroke 2019; 50: 754-757.
18. Nguyen TH, Gall S, Cadilhac DA, et al. Processes of stroke
unit care and outcomes at discharge in Vietnam: findings from
the registry of stroke care quality (RES-Q) in a major public
hospital. J Stroke Med 2019; 2: 119-127.
19. Nguyen TQ, Truong ALT, Phan HTK, et al. Bridging therapy
and direct thrombectomy for acute ischemic stroke: a prospective
cohort study. J Stroke Med 2020; 3: 124-130.
20. Groot AE, Treurniet KM, Jansen IGH, et al. Endovascular
treatment in older adults with acute ischemic stroke in the MR
CLEAN Registry. Neurology 2020; 95: e131-e139.
21. Nogueira RG and Ribó M. Endovascular treatment of acute
stroke. Stroke 2019; 50: 2612-2618.
22. Nguyen TN, Abdalkader M, Nagel S, et al. Noncontrast computed
tomography vs computed tomography perfusion or
magnetic resonance imaging selection in late presentation of
stroke with large-vessel occlusion. JAMA Neurol 2022; 79:
22-31.
23. Seker F, Qureshi MM, Möhlenbruch MA, et al. Reperfusion
without functional independence in late presentation of
stroke with large vessel occlusion. Stroke 2022; 53: 3594-
3604.
24. Siegler JE, Qureshi MM, Nogueira RG, et al. Endovascular vs
medical management for late anterior large vessel occlusion
with prestroke disability: analysis of CLEAR and RESCUEJapan.
Neurology 2023; 100: e751-e763.
25. Mohamed GA, Nogueira RG, Essibayi MA, et al. Tissue clock
beyond time clock: endovascular thrombectomy for patients
with large vessel occlusion stroke beyond 24 hours. J Stroke
2023; 25: 282-290.
26. de Havenon A, Zaidat OO, Amin-Hanjani S, et al. Large vessel
occlusion stroke due to intracranial atherosclerotic disease:
identification, medical and interventional treatment, and outcomes.
Stroke 2023; 54: 1695-1705.
27. Kobeissi H, Ghozy S, Adusumilli G, et al. Endovascular
therapy for stroke presenting beyond 24 hours: a systematic
review and meta-analysis. JAMA Netw Open 2023; 6:
e2311768.
28. Nguyen TN, Klein P, Berberich A, et al. Late window imaging
selection for endovascular therapy of large vessel occlusion
stroke: an international survey. Stroke 2022; 3: 000595.
International Journal of Stroke, 19(3)

WSO - March 2024

Table of Contents for the Digital Edition of WSO - March 2024

Contents
WSO - March 2024 - Cover1
WSO - March 2024 - Cover2
WSO - March 2024 - 245
WSO - March 2024 - Contents
WSO - March 2024 - 247
WSO - March 2024 - 248
WSO - March 2024 - 249
WSO - March 2024 - 250
WSO - March 2024 - 251
WSO - March 2024 - 252
WSO - March 2024 - 253
WSO - March 2024 - 254
WSO - March 2024 - 255
WSO - March 2024 - 256
WSO - March 2024 - 257
WSO - March 2024 - 258
WSO - March 2024 - 259
WSO - March 2024 - 260
WSO - March 2024 - 261
WSO - March 2024 - 262
WSO - March 2024 - 263
WSO - March 2024 - 264
WSO - March 2024 - 265
WSO - March 2024 - 266
WSO - March 2024 - 267
WSO - March 2024 - 268
WSO - March 2024 - 269
WSO - March 2024 - 270
WSO - March 2024 - 271
WSO - March 2024 - 272
WSO - March 2024 - 273
WSO - March 2024 - 274
WSO - March 2024 - 275
WSO - March 2024 - 276
WSO - March 2024 - 277
WSO - March 2024 - 278
WSO - March 2024 - 279
WSO - March 2024 - 280
WSO - March 2024 - 281
WSO - March 2024 - 282
WSO - March 2024 - 283
WSO - March 2024 - 284
WSO - March 2024 - 285
WSO - March 2024 - 286
WSO - March 2024 - 287
WSO - March 2024 - 288
WSO - March 2024 - 289
WSO - March 2024 - 290
WSO - March 2024 - 291
WSO - March 2024 - 292
WSO - March 2024 - 293
WSO - March 2024 - 294
WSO - March 2024 - 295
WSO - March 2024 - 296
WSO - March 2024 - 297
WSO - March 2024 - 298
WSO - March 2024 - 299
WSO - March 2024 - 300
WSO - March 2024 - 301
WSO - March 2024 - 302
WSO - March 2024 - 303
WSO - March 2024 - 304
WSO - March 2024 - 305
WSO - March 2024 - 306
WSO - March 2024 - 307
WSO - March 2024 - 308
WSO - March 2024 - 309
WSO - March 2024 - 310
WSO - March 2024 - 311
WSO - March 2024 - 312
WSO - March 2024 - 313
WSO - March 2024 - 314
WSO - March 2024 - 315
WSO - March 2024 - 316
WSO - March 2024 - 317
WSO - March 2024 - 318
WSO - March 2024 - 319
WSO - March 2024 - 320
WSO - March 2024 - 321
WSO - March 2024 - 322
WSO - March 2024 - 323
WSO - March 2024 - 324
WSO - March 2024 - 325
WSO - March 2024 - 326
WSO - March 2024 - 327
WSO - March 2024 - 328
WSO - March 2024 - 329
WSO - March 2024 - 330
WSO - March 2024 - 331
WSO - March 2024 - 332
WSO - March 2024 - 333
WSO - March 2024 - 334
WSO - March 2024 - 335
WSO - March 2024 - 336
WSO - March 2024 - 337
WSO - March 2024 - 338
WSO - March 2024 - 339
WSO - March 2024 - 340
WSO - March 2024 - 341
WSO - March 2024 - 342
WSO - March 2024 - 343
WSO - March 2024 - 344
WSO - March 2024 - 345
WSO - March 2024 - 346
WSO - March 2024 - 347
WSO - March 2024 - 348
WSO - March 2024 - 349
WSO - March 2024 - 350
WSO - March 2024 - 351
WSO - March 2024 - 352
WSO - March 2024 - 353
WSO - March 2024 - 354
WSO - March 2024 - 355
WSO - March 2024 - 356
WSO - March 2024 - 357
WSO - March 2024 - 358
WSO - March 2024 - 359
WSO - March 2024 - 360
WSO - March 2024 - 361
WSO - March 2024 - 362
WSO - March 2024 - 363
WSO - March 2024 - 364
WSO - March 2024 - 365
WSO - March 2024 - 366
WSO - March 2024 - 367
WSO - March 2024 - 368
WSO - March 2024 - 369
WSO - March 2024 - 370
WSO - March 2024 - 371
WSO - March 2024 - 372
WSO - March 2024 - Cover3
WSO - March 2024 - Cover4
https://europe.nxtbook.com/nxteu/sageuk/wso_202404
https://europe.nxtbook.com/nxteu/sageuk/ukstrokeforum_202402_supp
https://europe.nxtbook.com/nxteu/sageuk/wso_202403
https://europe.nxtbook.com/nxteu/sageuk/wso_202402
https://europe.nxtbook.com/nxteu/sageuk/wso_202401
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_US_UKOnly
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_ROW
https://europe.nxtbook.com/nxteu/sageuk/wso_2023101
https://europe.nxtbook.com/nxteu/sageuk/wso_202308
https://europe.nxtbook.com/nxteu/sageuk/wso_202307
https://europe.nxtbook.com/nxteu/sageuk/wso_202306
https://europe.nxtbook.com/nxteu/sageuk/wso_202304
https://europe.nxtbook.com/nxteu/sageuk/wso_202303
https://europe.nxtbook.com/nxteu/sageuk/wso_202302
https://europe.nxtbook.com/nxteu/sageuk/wso_202301
https://www.nxtbookmedia.com